ArticleChinese herbal medicines2026
Integrated network pharmacology and metabolomics to analyze the mechanism of Shaofu Zhuyu Decoction in treatment of dysmenorrhea of cold coagulation and blood stasis.
Article in Chinese herbal medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To study the mechanism of Shaofu Zhuyu Decoction (SFZYD) in treating primary dysmenorrhea (PD) with cold coagulation and blood stasis based on metabonomics and network pharmacology. Methods: The disease model of primary dysmenorrhea in rats with cold coagulation and blood stasis was established according to the previous research methods. The model of cold coagulation and blood stasis was built with ice water bath, and the model of PD was built with estradiol and oxytocin injection.The success of modeling was judged according to the physiological condition of rats, the change of body weight, the number of twisting and the change of uterine blood flow. UPLC-Q/TOF MS technique was used to identify the components and their main components in plasma in the Wenjing group (WJ, means warming channel), Huoxue group (HX, means activating blood), and Quanfang group (QF, means complete prescription) group, and a "compound-target-pathway" network was constructed by network pharmacology. Untargeted metabolomics studies were applied to screen out endogenous differential metabolites and analyze their related metabolic pathways. The analgesic effect, pathological morphology and inflammatory mediators were evaluated, and the pathway targets were verified. Results: A total of 93 chemical components and 22 components in plasma were identified. A total of 52 potential targets of SFZYD for primary dysmenorrhea were identified by network pharmacological analysis, and 12 endogenous differential metabolites and four related metabolic pathways were screened out by metabonomics. The possible targets and pathways of action of the components of SFZYD into blood were analyzed by network pharmacology, and the results showed that it can widely act on the proteins and pathways related to thrombosis, new angiogenesis, vasodilation, inflammatory immune response and central sedation. Body torsion test showed that drug administration could reduce the frequency of body twisting in dysmorrhea rats, ELISAs showed that SFZYD could inhibit the release of inflammatory factors TNF- Conclusion: Based on the research idea of "disease-syndrome-prescription-medicine"combination, this study discussed the internal relationship of SFZYD's drug property, functional taste and efficacy. The substance basis of "warm property and pungent taste" in the WJ group reflects pungent taste is dispersive and propulsive, the warm property can dispel cold, to help
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.